Cargando…
Statins Enhance the Molecular Response in Chronic Myeloid Leukemia when Combined with Tyrosine Kinase Inhibitors
SIMPLE SUMMARY: Approximately 50–60% of patients with chronic myeloid leukemia (CML) achieve a stable deep molecular response (DMR) after tyrosine kinase inhibitor (TKI) therapy. The achievement of DMR is a prerequisite for treatment-free remission. Repurposing statins is a straightforward strategy...
Autores principales: | Jang, Hyeok-Jae, Woo, Young-Min, Naka, Kazuhito, Park, Jong-Ho, Han, Ho-Jae, Kim, Hee-Jin, Kim, Sun-Hee, Ahn, Jae-Sook, Kim, Taehyung, Kimura, Shinya, Zarabi, Sarah, Lipton, Jeffrey H., Minden, Mark D., Jung, Chul-Won, Kim, Hyeoung-Joon, Kim, Jong-Won, Kim, Dennis Dong Hwan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582667/ https://www.ncbi.nlm.nih.gov/pubmed/34771705 http://dx.doi.org/10.3390/cancers13215543 |
Ejemplares similares
-
HMGCLL1 is a predictive biomarker for deep molecular response to imatinib therapy in chronic myeloid leukemia
por: Park, Jong-Ho, et al.
Publicado: (2018) -
Clinical Significance of bZIP In-Frame CEBPA-Mutated Normal Karyotype Acute Myeloid Leukemia
por: Ahn, Seo-Yeon, et al.
Publicado: (2023) -
Assessment of a new genomic classification system in acute myeloid leukemia with a normal karyotype
por: Ahn, Jae-Sook, et al.
Publicado: (2017) -
FLT3 mutations in acute myeloid leukemia: a review focusing on clinically applicable drugs
por: Ahn, Jae-Sook, et al.
Publicado: (2022) -
5-Hydroxymethylcytosine correlates with epigenetic regulatory mutations, but may not have prognostic value in predicting survival in normal karyotype acute myeloid leukemia
por: Ahn, Jae-Sook, et al.
Publicado: (2016)